Spero COO sells shares to cover RSU taxes

Spero Therapeutics Chief Operating Officer Timothy Keutzer reported an automatic sale of common stock tied to tax obligations.

Rhea-AI Filing Summary

Spero Therapeutics Chief Operating Officer Timothy Keutzer reported an automatic sale of common stock tied to tax obligations. On 02/06/2026, 18,652 shares of common stock were sold at $2.36 per share to cover tax withholding arising from restricted stock unit (RSU) vesting.

After this transaction, Keutzer beneficially owned 742,506 shares of Spero Therapeutics common stock in direct form. The filing explains that the sale was a mandatory "sell to cover" transaction to fund taxes and was not a discretionary trade by the executive.

Insider Trade Summary

Net Seller: 18,652 shares

Net Sell 1 txn

Insider Keutzer Timothy

Role Chief Operating Officer

Sold 18,652 shs ($44K)

Type	Security	Shares	Price	Value
Sale	Common Stock	18,652	$2.36	$44K

Holdings After Transaction: Common Stock — 742,506 shares (Direct)

Footnotes (1)

1. F1. Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did SPRO Chief Operating Officer Timothy Keutzer report?

Timothy Keutzer reported an automatic sale of 18,652 shares of Spero Therapeutics common stock. The shares were sold at $2.36 each to cover tax withholding obligations triggered by vesting RSUs, rather than representing a discretionary open-market sale by the executive.

How many SPRO shares does Timothy Keutzer hold after this Form 4 transaction?

Following the reported transaction, Timothy Keutzer beneficially owned 742,506 shares of Spero Therapeutics common stock. These shares are reported as directly held, indicating continued substantial equity exposure to the company after the tax-related sell-to-cover transaction disclosed in the Form 4.

Was the SPRO insider sale by Timothy Keutzer a discretionary trade?

No, the sale was not discretionary. The footnote states the 18,652 shares were sold automatically under a “sell to cover” arrangement to satisfy tax withholding obligations from vesting RSUs, meaning the transaction was driven by tax requirements rather than an elective share sale.

At what price were the SPRO shares sold in Timothy Keutzer’s Form 4 filing?

The 18,652 Spero Therapeutics common shares were sold at $2.36 per share. This price reflects the execution level for the tax-related sell-to-cover transaction that funded Keutzer’s withholding obligations upon the vesting of restricted stock units granted by the company.

What is the significance of the RSU-related tax sale disclosed by SPRO’s COO?

The filing shows shares were sold solely to cover taxes on vesting RSUs, a common administrative step in equity compensation. It indicates the COO continues to hold 742,506 shares directly, so the transaction does not reflect a broad reduction of his overall ownership position.

What role does Timothy Keutzer hold at Spero Therapeutics (SPRO)?

Timothy Keutzer is reported as the Chief Operating Officer of Spero Therapeutics. His status as an officer triggers Section 16 reporting duties, so transactions in the company’s common stock, including this RSU-related sell-to-cover sale, must be disclosed on Form 4 filings with the SEC.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/09/2026 - 09:09 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Keutzer Timothy

(Last) (First) (Middle)

C/O SPERO THERAPEUTICS, INC.

675 MASSACHUSETTS AVENUE, 14TH FLOOR

(Street)

CAMBRIDGE MA 02139

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Spero Therapeutics, Inc. [ SPRO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/06/2026		S(1)		18,652(1)	D	$2.36	742,506	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

	/s/ Maegan Deare, Attorney-in-Fact for Timothy Keutzer	02/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.